Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dallin Gambles

Physician Assistant, Medical Rexburg, ID Physician Assistant

NPI 1760533400 CMS profile 10974274

380 Walker Dr, Rexburg, ID 83440

Open in the dashboard

General payments

$10,240

532 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dallin Gambles of Rexburg, ID is reported in the CMS Open Payments database as having received $10,240 across 532 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,752 131
2024 General $2,202 117
2023 General $1,971 104
2022 General $1,862 96
2021 General $1,453 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dallin Gambles
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Dallin Gambles were reported at $2,752. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Dallin Gambles Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,453 $156 $41–$563 $132
2022 $1,862 $185 $55–$649 $149
2023 $1,971 $199 $58–$717 $160
2024 $2,202 $206 $62–$740 $164
2025 $2,752 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $793 62 payments
  2. AstraZeneca Pharmaceuticals LP $597 30 payments
  3. Genzyme Corporation $587 29 payments
  4. Merck Sharp & Dohme Corporation $568 28 payments
  5. Novartis Pharmaceuticals Corporation $523 28 payments
  6. Daiichi Sankyo Inc. $446 24 payments
  7. Genentech USA, Inc. $428 24 payments
  8. Janssen Biotech, Inc. $405 24 payments
  9. E.R. Squibb & Sons, L.L.C. $338 18 payments
  10. Astellas Pharma US Inc $325 13 payments
  11. Other $5,231 252 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,674 525 payments
  2. Education $566 7 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $552 27 payments
  2. XTANDI $346 23 payments
  3. ENHERTU $333 16 payments
  4. OPDIVO $326 17 payments
  5. SARCLISA $318 16 payments
  6. IMBRUVICA $313 13 payments
  7. KISQALI $257 14 payments
  8. IBRANCE $233 17 payments
  9. VENCLEXTA $223 13 payments
  10. VERZENIO $223 12 payments
  11. Other $9,726 540 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

578

Median for Physician Assistant: 241

Drug cost

$644,677

Median for Physician Assistant: $4,110

Branded share of claims

23.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kisqali Ribociclib Succinate Brand 20 $300,222
Jakafi Ruxolitinib Phosphate Brand 13 $229,583
Abiraterone Acetate Generic 24 $95,150
Eliquis Apixaban Brand 11 $10,827
Celecoxib Generic 20 $1,119
Ondansetron Odt Ondansetron Brand 33 $758
Anagrelide Hcl Generic 12 $751
Anastrozole Generic 50 $746
Tamoxifen Citrate Generic 19 $685
Oxycodone Hcl Generic 29 $651

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$43,920

Medicare's payments for the services billed

Medicare patients

176

Average age 74

Services billed

531

106 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Cancer 45%
Diabetes 32%
Ischemic heart disease 23%
Chronic kidney disease 20%
Atrial fibrillation 19%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 76 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VONJO
  • Sobi, Inc $94
$94 — —
ENHERTU
  • Daiichi Sankyo Inc. $82
$82 — —
AYVAKIT
  • Blueprint Medicines Corporation $78
$78 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $73
$73 — —
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 76 with Patron

Records

532 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record